Revvity Inc. (RVTY) is making a move that screams "GLP-1." On Wednesday, the company announced it has agreed to acquire Human Cell Design, a French firm specializing in human cell models for studying diabetes, obesity, and other metabolic diseases. The deal is expected to close in the fourth quarter of 2026, pending regulatory approvals and standard closing conditions. Financial terms were not disclosed.
Revvity ended the second quarter of 2026 with cash and cash equivalents of $1.02 billion, so it has the firepower to make this happen without breaking a sweat.
Why Human Cell Models Matter
Here's the thing: drug discovery for metabolic diseases is hot, especially with GLP-1 therapies taking the world by storm. But to develop these drugs, researchers need realistic human cell models to test their ideas. That's where Human Cell Design comes in.
The star of the show is Human Cell Design's EndoC-βH5 model, which lets scientists study human pancreatic beta cell function in the context of diabetes and obesity. The company also offers specialized reagents, preclinical research services, and its NatLine cell-line development platform.
Revvity plans to integrate these models into its Life Sciences portfolio, combining them with its own screening, detection, automation, and analysis technologies. Think of it as adding a high-powered microscope to an already well-equipped lab.
What This Means for Drug Development
Revvity CEO Prahlad Singh said the deal will pair Human Cell Design's models with Revvity's HTRF, AlphaLISA, and ATPlite assays, as well as its high-content screening platform. That's a mouthful, but essentially it means researchers can now use these human cell models in Revvity's existing workflows, making drug screening faster and more relevant.
The technology could also play a role in regenerative medicine for Type 1 diabetes and cell-based therapies as they move toward commercialization. So this isn't just about the here and now; it's about positioning for the future.
As for the market's reaction, Revvity shares were trading down 0.27% at $126.74 during premarket trading on Wednesday, according to market data. A slight dip, but nothing to write home about.
In a world where everyone is chasing the next big obesity drug, Revvity is betting that the tools to make those drugs will be just as valuable. Smart move.
